Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

In the letters, sent to Eli Lilly & Co., Novo Nordisk A/S, Pfizer Inc. and others, Trump insisted companies immediately lower ...

A potentially billion-dollar acquisition of Gilgamesh Pharmaceuticals suggested big pharma may finally be willing to place ...

As pharmaceutical import tariffs take shape in Europe, President Donald Trump is rounding out the week by spotlighting ...

AbbVie ABBV reported second-quarter revenue of $15.4 billion (6.6% growth) and adjusted diluted earnings per share of $2.97 ...

Discover AbbVie's standout Q2 2025 earnings insights, with strong Skyrizi & Rinvoq growth, raised revenue guidance, and robust R&D progress driving ...

AbbVie stock rose after the drugmaker reported second-quarter earnings per share of $2.97 on revenue of $15.4 billion, ...

AbbVie Inc. ABBV reported second-quarter 2025 adjusted EPS of $2.97, which beat the Zacks Consensus Estimate of $2.89. The ...

AbbVie Inc. (NYSE: ABBV) stock is up nearly 2% in midday trading after delivering a beat-and-raise in its second-quarter 2025 ...

Psychedelic stocks rise after report on AbbVie's (ABBV) deal talks to acquire Gilgamesh Pharmaceuticals in a transaction ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...